


Review

# Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review

Greta Brezgyte <sup>†</sup>, Vinay Shah <sup>†</sup> , Daria Jach and Tatjana Crnogorac-Jurcevic <sup>\*</sup>

Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; g.brezgyte@qmul.ac.uk (G.B.); vinay.shah8@nhs.net (V.S.); d.jach@qmul.ac.uk (D.J.)

<sup>\*</sup> Correspondence: t.c.jurcevic@qmul.ac.uk

<sup>†</sup> Shared first authorship.

**Simple Summary:** Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 90% of all pancreatic cancers, is an extremely aggressive and lethal disease. It is considered a silent killer due to a largely asymptomatic course and late clinical presentation. Earlier detection of the disease would likely have a great impact on changing the currently poor survival figures for this malignancy. In this comprehensive review, we assessed over 4000 reports on non-invasive PDAC biomarkers in the last decade. Applying the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, we selected and reviewed in more detail 49 relevant studies reporting on the most promising candidate biomarkers. In addition, we also highlight the present challenges and complexities of translating novel biomarkers into clinical use.

**Abstract:** Pancreatic ductal adenocarcinoma (PDAC) carries a deadly diagnosis, due in large part to delayed presentation when the disease is already at an advanced stage. CA19-9 is currently the most commonly utilized biomarker for PDAC; however, it lacks the necessary accuracy to detect precursor lesions or stage I PDAC. Novel biomarkers that could detect this malignancy with improved sensitivity (SN) and specificity (SP) would likely result in more curative resections and more effective therapeutic interventions, changing thus the present dismal survival figures. The aim of this study was to systematically and comprehensively review the scientific literature on non-invasive biomarkers in biofluids such as blood, urine and saliva that were attempting earlier PDAC detection. The search performed covered a period of 10 years (January 2010—August 2020). Data were extracted using keywords search in the three databases: MEDLINE, Web of Science and Embase. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was applied for study selection based on establishing the risk of bias and applicability concerns in Patient Selection, Index test (biomarker assay) and Reference Standard (standard-of-care diagnostic test). Out of initially over 4000 published reports, 49 relevant studies were selected and reviewed in more detail. In addition, we discuss the present challenges and complexities in the path of translating the discovered biomarkers into the clinical setting. Our systematic review highlighted several promising biomarkers that could, either alone or in combination with CA19-9, potentially improve earlier detection of PDAC. Overall, reviewed biomarker studies should aim to improve methodological and reporting quality, and novel candidate biomarkers should be investigated further in order to demonstrate their clinical usefulness. However, challenges and complexities in the path of translating the discovered biomarkers from the research laboratory to the clinical setting remain and would have to be addressed before a more realistic breakthrough in earlier detection of PDAC is achieved.

**Keywords:** pancreatic ductal adenocarcinoma; systematic review; biomarkers; QUADAS-2; early detection; non-invasive



**Citation:** Brezgyte, G.; Shah, V.; Jach, D.; Crnogorac-Jurcevic, T.

Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review. *Cancers* **2021**, *13*, 2722. <https://doi.org/10.3390/cancers13112722>

Academic Editor: Adam E. Frampton

Received: 22 April 2021

Accepted: 27 May 2021

Published: 31 May 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 90% of all pancreatic cancers, is an extremely aggressive disease and one of the most lethal

cancers. Its incidence almost equals its mortality, and it has a 5-year survival of only around 9% [1,2]. It caused 7800 deaths in the United Kingdom (UK) in 2018 alone, and, according to GLOBOCAN, there were 458,918 new cases of pancreatic cancer and 432,242 pancreatic cancer-related deaths worldwide in the same year [3]. Furthermore, PDAC incidence is steadily increasing [4–7].

PDAC is considered a silent killer due to a largely asymptomatic course, late clinical presentation, and rapid progression [8], with fewer than 20% of PDAC patients being diagnosed at early, resectable stages I and II [9,10]. Importantly, if PDAC is detected when still a localized disease, the 5-year survival is around 32% [11], but it can approach 70% following resection of incidentally diagnosed stage I tumors [12–14]. It is estimated that it takes at least 10 years between initiating mutation and the birth of parental founder [15]; combined with an increased PDAC incidence with age [5], resectable PDAC has likely already been growing for a number of years. We therefore further on use the term “earlier” rather than “early” stage.

To date, there exists no reliable, non-invasive screening test, either molecular or imaging-based, that will allow accurate PDAC detection at an earlier stage in asymptomatic patients. The conventional methods such as computerized tomography, magnetic resonance imaging or endoscopic ultrasonography are expensive and have low sensitivity (SN) and specificity (SP) for detection of small premalignant lesions [16]. Furthermore, the deep anatomic location of the pancreas makes detection of small-localized tumors unlikely during a routine abdominal examination [17].

In contrast, testing for biomarkers in body fluids such as serum, plasma, urine or saliva is minimally invasive, relatively inexpensive and could allow for earlier PDAC diagnosis [18]. The current gold-standard serum biomarker for PDAC is carbohydrate antigen 19-9 (CA19-9), also known as sialylated Lewis (a) antigen. It is a product of exocrine epithelial cells and various mucins secreted by PDAC cells that are normally found on the surface of erythrocytes [19]. The test was approved by the U.S. Food and Drug Administration (FDA) in 2002 [20]. However, it is recommended to be used only for disease monitoring and prognosis, since the performance of CA19-9 as a diagnostic biomarker is limited by poor SN, false-negative results in the individuals with Lewis negative phenotype and increased false positivity in several benign and malignant biliary disorders [21]. Furthermore, CA19-9 is not recommended as a screening marker due to its low positive predictive value (0.5–0.9%) [22–24].

The accuracy of any tumor biomarkers assay, including CA19-9, is linked to the concept of threshold, or cut-off [25]. The CA19-9 cut-off values differ significantly between studies due to the lack of an international standard for CA19-9 and the difference in the assay design and instrument utilized [26]. When the two most frequently used assays for measuring CA19-9, Abbott Architect CA 19-9XR and Roche Elecsys CA19-9, were compared, despite being based on the same monoclonal antibody 1116-NS-19-9 [27], the Abbott assay measured significantly lower CA19-9 values than the Roche one in healthy and benign cases [28]. While the upper reference limit of 37 U/mL, reaching mean SN and SP of 81% and 90%, respectively, as first reported by Steinberg [29], is still able to sufficiently differentiate between controls and PDAC, the CA19-9 values obtained by different methods should not be used interchangeably, the method utilized should be clearly stated and the patients should be monitored using the same assay [28,30]. Thus, despite its role as the principle serological test for PDAC, the standardization of the laboratory testing and correct interpretation of high serum CA19-9 levels with the adequately established cut off has not yet been achieved [31]. The search for a new non-invasive PDAC biomarker with superior SN and SP to CA19-9, which will be easily identifiable and robustly measured in a fully standardized fashion in biofluids, is therefore being actively pursued.

Recent advances in molecular techniques have empowered the discovery of novel biomarkers for earlier detection of PDAC, resulting in a significant and constantly growing body of literature. Despite the discovery of thousands of biomarkers, relatively few have been adequately tested and validated, making the assessment of their potential

challenging [32]. This sparked an EDRN (The Early Detection Research Network) workshop at National Cancer Institute (NCI) in 2016, where a selection of the most promising studies was reported [33]. A comprehensive update and critically appraised resource of information on potentially useful novel biomarkers for PDAC is, however, needed.

In the present study, we reviewed over 4000 articles and further assessed 49 published studies from the last decade describing biomarkers in serum, plasma, urine and saliva for earlier PDAC detection, in conjunction with serum CA 19-9, when available. We utilized the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) to assess the quality of the selected studies and highlighted their potential clinical utility and limitations for earlier PDAC detection.

## 2. Methods

Two of the authors (G.B. and V.S.) independently conducted a systematic search of MEDLINE, Web of Science and Embase and assessed all the articles published between January 2010 and August 2020. A robust reproducible search strategy was created which utilized the MESH terms “Pancreas OR Pancreatic” AND “Ductal Adenocarcinoma OR PDAC OR Cancer OR Malignancy OR Adenocarcinoma OR Tumour OR Tumor” AND “Liquid Biopsy OR Biomarkers OR Screening OR Stool OR Markers OR Marker OR Urine OR Saliva OR Blood OR Non-invasive OR Non Invasive OR Fluid Biopsy OR Fluid Phase Biopsy OR Detection OR Diagnosis OR Diagnose OR Screen” to search for the potential biomarkers specific for this disease. The filters were adjusted to show the results for studies in the English language only. The article type was set to only include clinical and observational studies in Medline. In Medline and Embase, titles and abstracts were searched. In Web of Science, only titles were searched. PRISMA guidelines were used to assist in the structuring of this systematic review [34]. The inclusion and exclusion criteria for selecting the studies are listed in Table 1.

**Table 1.** Inclusion and Exclusion Criteria for study selection.

Inclusion Criteria
1. Pancreatic Ductal Adenocarcinoma 2. Non-invasive method of obtaining a liquid biopsy e.g., plasma, serum, urine, saliva, stool 3. Original data with reported AUC, SN and SP of a proposed biomarker 4. Human studies 5. Manuscripts from January 2010 until August 2020
Exclusion Criteria
1. No specification of what type of pancreatic cancer it was 2. Invasive procedures to obtain the biomarker e.g., tissue biopsy 3. No recorded data either of SN, SP and/or AUC for the tested biomarker 4. Biomarker used for a purpose other than detection e.g., prognostic biomarkers 5. Abstracts, Conference reports/writings, NHS reports, Review Articles

Abbreviations: AUC—Area Under the ROC (Receiver Operating Characteristic) Curve, SN—Sensitivity, SP—Specificity, NHS—National Health Service in UK.

Assessment of the methodological quality of reviewed articles was performed according to QUADAS-2, a validated quality assessment tool commonly used to assess the methodology of investigated studies, and as a measure to improve diagnostic accuracy [35]. With QUADAS-2, we were able to appraise three key domains, namely Patient Selection, Index Test and Reference Standard, for both risk of bias and applicability. For the Patients selection, we assessed if the sample groups were well described and if patient spectrum was representative of the disease. We also assessed if the selection of the controls was appropriate, i.e., if, in addition to healthy controls, samples collected from patients with benign pancreatic diseases at risk for progressing to PDAC were also included. Within the Applicability concerns, we assessed if the data for PDAC stages I/II were reported, as we were aiming to review biomarkers for earlier detection of PDAC. For the Index test (biomarker assay), we appraised how well the assay was described and executed and the

results interpreted (SN/SP/AUC with 95% confidence intervals (CIs)) and if the data were split into training and validation sets. To increase the validity of the results, QUADAS-2 also recommends that researchers do not know which study group each patient belongs to (“blinding”) in order to reduce the effects of any foreknowledge in the interpretation of the biomarker assay results [36]. QUADAS-2 includes the need to specify a threshold value for the Index test prior to obtaining the results; however, this is not suitable for newly discovered biomarkers, where one of the aims is to determine the appropriate cut-offs with regards to the SN, SP and AUC. For the Reference Standard, we assessed if the study specifies that PDAC diagnosis was confirmed by histology and if the staging was pathological or clinical. However, as biomarker discovery studies are typically performed on retrospectively collected samples with an already established diagnosis, we additionally included a comparison of the new biomarker with CA19-9. Flow and Timing were excluded from our QUADAS-2 scoring, as it was difficult to assess this parameter, i.e., in the majority of the studies, it was unclear in what time frame were the diagnostic biopsy or imaging performed in respect to the sample collection and the biomarker testing.

### 3. Results and Discussion

A PRISMA flow diagram demonstrating the search strategy and study selection criteria that were applied is shown in Figure 1.





Figure 1. PRISMA Flow diagram of the search strategy and study selection.

The overall quality of the 49 selected and reviewed studies is illustrated in Figure 2.



**Figure 2.** Graphical representation of the overall quality of the selected studies.

In Figure 2 it is evident that the majority of the studies (70%) had a low risk of bias in the Reference Standard domain, as the information on histological confirmation that samples originated from PDAC was specified. The unclear bias in this domain seen in approximately 30% of the studies was due to the absence of comparison of biomarkers with CA19-9. High risk of bias in the Index test (biomarker assay) was seen in 36% of studies and was associated with missing information on if the samples were analyzed in the blinded fashion. The lack of clarity, which was seen in the following 36% of the studies, was due to absence of robust statistical analysis of the data, i.e., splitting of the data into the training and the validation sets. Regarding patient selection criteria, around 20% of studies did not compare PDAC results to appropriate benign controls, leading to a high risk of bias. Around 20% of studies raised concerns about the applicability of the biomarkers for earlier PDAC detection, as they were not assessed in resectable stage I–II PDAC.

A graphical summary of the QUADAS-2 results with the descriptive score for each of the selected studies is presented in a tabular form in supplementary Appendix A, Table A1. Table 2 summarizes the key findings from all 49 studies included in this review.

Table 2. Key findings from included studies.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Gold et al., 2010 [37]	Serum	PAM4	68 PDAC, 19 HC	PDAC vs. HC	82.0	95.0	0.92 (0.84–0.97)
Joergensen et al., 2010 [38]	Serum	CA19-9	51 PDAC, 52 HC	PDAC vs. HC	86.0	73.0	0.84 (0.77–0.92)
		MMP-9			58.8	34.6	0.50 (0.39–0.61)
Marten et al., 2010 [39]	Plasma	siC3b	157 PDAC, 38 HC	2–4mo prior radiologically defined recurrence	54.0	94.0	0.85
		siC3b		0–2mo prior radiologically defined recurrence	62.0	94.0	0.84
Brand et al., 2011 [17]	Serum	CA19-9	160 PDAC, 74 BPD, 107 HC	TS: PDAC vs. HC	57.2	90.0	0.83 (0.81–0.86)
		CA19-9 + ICAM-1 + OPG		PDAC vs. BPD	88.0	90.0	0.93 (0.91–0.95)
		CA19-9 + CEA +TIMP-1		PDAC vs. HC	76.0	90.0	0.86
		CA19-9		VS: PDAC vs. BPD	56.4	90.0	0.82 (0.78–0.86)
		CA19-9 + ICAM-1 + OPG	173 PDAC, 70 BPD, 120 HC	PDAC vs. HC	78.0	94.1	0.91 (0.88–0.95)
		CA19-9 + CEA +TIMP-1		PDAC vs. BPC	71.2	88.6	0.83 (0.88–0.89)
		CA19-9		PDAC vs. BPC	52.1	90.2	0.78 (0.74–0.83)
Park et al., 2012 [21]	Serum	Cathepsin D	109 PDAC, 40 HC, 30 CP	TS: PDAC vs. HC + CP	54.0	80.0	0.67
		MMP-7			72.0	80.0	0.81
		CA19-9			74.0	80.0	0.84
		CA19-9 + Cathepsin D + MMP-7			88.0	80.0	0.90 (p = 0.002)
		Cathepsin D	129 PDAC, 74 HC, 72 CP	VS: PDAC vs. HC + CP	53.0	79.0	0.65
		MMP-7			65.0	79.0	0.77
		CA19-9			78.0	84.0	0.88
		CA19-9 + Cathepsin D + MMP-7			89.0	77.0	0.91 (p = 0.002)
Capello et al., 2013 [40]	Serum	EZR-autoantibody	69 PDAC, 46 CP, 60 HC, 12 Aim, 50 Non-PDAC	PDAC vs. HC + CP + Aim	93.2	75.5	0.90
				PDAC vs. non-PDAC cancer	94.9	96.4	0.99

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Gold et al., 2013 [41]	Serum	PAM4	298 PDAC, 120 BPD, 50 CP	PDAC vs. BPD	74.0	85.0	0.87 (p = 0.0001)
		CA19-9			77.0	73.0	0.85 (p = 0.0257)
		PAM4 + CA19-9			84.0	83.0	0.91
		PAM4		PDAC vs. CP	74.0	86.0	0.87 (p = 0.0001)
		CA19-9			77.0	68.0	0.84 (p = 0.0073)
		PAM4 + CA19-9			84.0	82.0	0.91
Kobayashi et al., 2013 [42]	Serum	Diagnostic Model *	43 PDAC, 42 HC	TS: PDAC vs. HC	86.0	88.1	0.93 (0.86–0.97)
		CA19-9			62.8	100.0	0.82 (0.70–0.90)
		CEA			44.2	97.6	0.80 (0.69–0.88)
		Diagnostic Model *	9 PDAC (stage 0-IIB), 41 HC, 23 CP	VS: PDAC stage 0-IIB vs. HC + CP	77.8	78.1	0.76 (0.66–0.86)
		CA19-9			55.6	85.9	0.79 (0.68–0.88)
		CEA			44.4	79.7	0.67 (0.55–0.76)
Li et al., 2013 [43]	Serum	CA19-9	41 PDAC, 19 HC, 35 CP	PC vs. HC	71.0	90.0	0.86
		miR-1290			88.0	84.0	0.96 (0.91–1.00)
		miR-146a			78.0	79.0	0.82 (0.71–0.92)
		miR-484		PDAC vs. CP	76.0	63.0	0.78
		CA19-9			71.0	63.0	0.71
		miR-1290			83.0	69.0	0.81 (0.71–0.91)
		miR-146a			73.0	80.0	0.78 (0.68–0.89)
		miR-484			75.0	69.0	0.75
Zhao et al., 2013 [44]	Serum	miR -192	70 PDAC, 40 HC	PDAC vs. HC	76.0	55.0	0.63 (0.51–0.75)
Chung et al., 2014 [45]	Serum	sCD40L	55 PDAC, 30 CP, 30 HC	VS: PDAC vs. CP vs. HC	80	85.5	0.88
		CA19-9			80	72.7	0.78
		CEA			68.9	60	0.70
Lee et al., 2014 [46]	Serum	CFB	41 PDAC, 44 HC, 12 CP, 31 HCC, 22 CC, 35 GC	PDAC vs. non-PDAC	73.1	97.9	0.958 (0.956–0.959)
		CA19-9			80.4	70.0	0.833 (0.829–0.837)
		CFB + CA19-9			90.1	97.2	0.986 (p < 0.001)



Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Nolen et al., 2014 [47]	Serum	CA19-9	343 PDAC, 227 HC	1–12 months	25.7	95.0	0.680
		CA19-9 + CEA		Pre-diagnostic PDAC	26.7	95.0	0.67
		CA19-9 + CEA + Cyfra 21-1		vs. HC	32.4	95.0	0.69
		CA19-9		12–35 months	17.2	95.0	0.63
		CA19-9 + CEA		Pre-diagnostic PDAC	28.1	95.0	0.66
		CA19-9 + CEA + Cyfra 21-1		vs. HC	29.7	95.0	0.66
Ren et al., 2014 [48]	Serum	IL-11p	44 PDAC, 30 HC	PDAC vs. HC	97.7	70.0	0.901 (p < 0.001)
Schultz et al., 2014 [49]	Serum	Index 1 (miR-145, -150, -223, -636)	143 PDAC, 18 CP, 69 HC	DC: PDAC vs. HC + CP	85.0	73.0	0.88 (0.85–0.92)
		Index 2 (miR-26b, -34a, -122, -126, -145, -150, -223, -505, -636, -885.5p)					
		CA19-9					
		Index 1 + CA19-9					
		Index 2 + CA19-9					
		85.0					
		86.0					
		0.93 (0.89–0.96)					
		88.0					
		92.0					
		0.87 (0.82–0.92)					
		85.0					
93.0							
0.88 (0.83–0.93)							
85.0							
97.0							
0.95 (0.92–0.98)							
Index 1	180 PDAC, 199 HC	TS: PDAC vs. HC	85.0	64.0	0.86 (0.82–0.90)		
Index 2							
CA19-9							
Index 1 + CA19-9							
Index 2 + CA19-9							
85.0							
85.0							
85.0							
86.0							
99.0							
0.90 (0.87–0.94)							
85.0							
95.0							
0.93 (0.90–0.96)							
85.0							
98.0							
0.97 (0.95–0.98)							
Index 1	86 PDAC, 7 CP, 44 HC	VS: PDAC vs. HC + CP	85.0	45.0	0.83 (0.76–0.90)		
Index 2							
CA19-9							
Index 1 + CA19-9							
Index 2 + CA19-9							
85.0							
85.0							
79.0							
88.0							
0.89 (0.83–0.95)							
85.0							
88.0							
0.93 (0.88–0.97)							
85.0							
86.0							
0.92 (0.87–0.96)							
Yang et al., 2014 [50]	Stool	miR-21	30 PDAC, 15 HC	PDAC vs. HC	90.0	66.7	0.80 (0.68–0.92)
		miR-155			76.7	73.3	0.72 (0.58–0.86)
		miR-216			86.7	60.0	0.73 (0.60–0.86)
		miR-216 + miR-21 + miR-155			83.3	83.3	0.87 (0.77–0.96)



Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Zhang et al., 2014 [51]	Serum	CA19-9 + Albumin + CRP + IL-8 CA19-9	163 PDAC (77 Early stage I-II), 109 BC, 200 HC	All stage PDAC vs. HC			
				All stage PDAC vs. HC	99.4	90.0	0.98 (0.97–1.00)
				Early stage PDAC vs. HC	80.6	90.0	0.85 (0.80–0.90)
				Early stage PDAC vs. HC	96.1	90.0	0.97 (0.95–1.00)
		CA19-9 + Albumin + CRP + IL-8 CA19-9	163 PDAC (77 Early stage I-II), 109 BC, 200 HC	Early stage PDAC vs. HC	72.7	90.0	0.83 (0.75–0.90)
				All stage PDAC vs. BC			
				All stage PDAC vs. BC	74.2	90.0	0.89 (0.86–0.93)
				Early stage PDAC vs. BC	53.4	90.0	0.75 (0.69–0.81)
CA19-9 + CO2 + CRP + IL-6 CA19-9	163 PDAC (77 Early stage I-II), 109 BC, 200 HC	Early stage PDAC vs. BC	75.3	90.0	0.87 (0.82–0.93)		
		Early stage PDAC vs. BC	40.3	90.0	0.69 (0.61–0.78)		
		Early stage PDAC vs. BC					
		Early stage PDAC vs. BC					
Debernardi et al., 2015 [52]	Urine	miR-143 miR-223 miR-30e miR-143 + miR-30e	6 PDAC (stage I), 26 HC	Stage I PDAC vs. HC	83.3	88.5	0.86 (0.70–1.00)
					83.3	76.9	0.80 (0.59–1.00)
					83.3	80.8	0.85 (0.67–1.00)
					83.3	96.2	0.92 (0.79–1.00)
Han et al., 2015 [53]	Serum	Dickkopf-1 (DKK1) CA19-9	140 PDAC, (62 Early stage I-II), 48 HC, 18 BPT, 26 CP	PDAC vs. HC + BPT + CP	89.3	79.4	0.92 (0.88–0.95)
					73.6	83.7	0.85 (0.80–0.90)
		Dickkopf-1 (DKK1) CA19-9	140 PDAC, (62 Early stage I-II), 48 HC, 18 BPT, 26 CP	PDAC vs. BPT + CP	89.3	72.7	0.89 (0.83–0.95)
					73.6	81.8	0.83 (0.77–0.89)
		Dickkopf-1 (DKK1) CA19-9	140 PDAC, (62 Early stage I-II), 48 HC, 18 BPT, 26 CP	Early-PDAC vs. HC + BPT + CP	85.5	79.3	0.89 (0.84–0.94)
			64.5	83.7	0.81 (0.74–0.89)		
Dickkopf-1 (DKK1) CA19-9	140 PDAC, (62 Early stage I-II), 48 HC, 18 BPT, 26 CP	Early-PDAC vs. BPT + CP	85.5	72.7	0.85 (0.78–0.93)		
			64.5	81.8	0.78 (0.70–0.87)		

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Melo et al., 2015 [54]	Serum	GPC1 + crExos CA19-9	190 PDAC, 100 HC, 26 BPD	DS: PDAC vs. HC + BPD	100.0 76.8	100.0 64.3	1.00 (0.99–1.00) 0.74 (0.70–0.83)
		GPC1 + crExos GPC1 (ELISA)	56 PDAC, 20 HC, 6 BPD	VS: PDAC vs. HC + BPD	100.0 82.1	100.0 75.0	1.00 (0.96–1.00) 0.78 (0.68–0.87)
Radon et al., 2015 [55]	Urine	LYVE1 REG1A TFF1 LYVE1 + REG1A + TFF1 + (Creatinine +Age)	143 PDAC (stage I-IV), 59 HC	TS: PDAC vs. HC	76.9 62.2 72.7 76.9	88.1 94.9 59.3 89.8	0.85 (0.80–0.90) 0.82 (0.77–0.88) 0.69 (0.61–0.77) 0.89 (0.85–0.94)
		LYVE1 REG1A TFF1 LYVE1 + REG1A + TFF1 + (Creatinine +Age)	56 PDAC (stage I-II), 61 HC		67.9 75.0 78.6 82.1	91.8 68.9 52.5 88.5	0.84 (0.77–0.91) 0.75 (0.66–0.84) 0.70 (0.60–0.79) 0.90 (0.84–0.96)
		LYVE1 + REG1A + TFF1 + (Creatinine +Age)	49 PDAC (stage I-IV), 28 HC	VS: PDAC vs. HC	75.5	100	0.92 (0.84–1.00)
		LYVE1 + REG1A + TFF1 + (Creatinine +Age)	56 PDAC (stage I-II), 61 HC		80.0	76.9	0.93 (0.84–1.00)
		Plasma CA19-9 Panel (LYVE1 + REG1A + TFF1) Panel + Plasma CA19-9	71 PDAC (stage I-II), 28 HC	Exploratory Comparison	83.1 93.0 94.4	92.9 92.9 100	0.88 (0.81–0.95) 0.97 (0.95–1.00) 0.99 (0.98–1.00)
		Ankeny et al., 2016 [56]	Serum	CTCs and KRAS mutation analysis	72 PDAC, 28 non-adenocarcinoma	PDAC vs. non-adenocarcinoma	78.0
Guo et al., 2016 [57]	Serum	DTNBP1 CA19-9	250 PDAC, 70 CP, 80 BBO, 150 HC	PDAC vs. BBO + CP + HC	81.9 76.3	84.7 52.5	0.85 (0.81–0.89) 0.74 (0.70–0.78)
		DTNBP1 CA19-9		PDAC vs. CP	73.9 66.3	78.9 73.2	0.80 (0.75–0.86) 0.69 (0.63–0.75)
		DTNBP1 CA19-9		PDAC vs. BBO	82.3 53.8	84.0 49.4	0.85 (0.80–0.89) 0.59 (0.53–0.65)

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Henriksen et al., 2016 [58]	Plasma	(Model13): age >65+ BMP3+ RASSF1A+ BNC1+ MESTv2+ TFPI2+ APC+ SFRP1 + SFRP2	95 PDAC, 97 CP, 27 "screened negative"	PDAC vs. screened negative + CP	73.0	83.0	0.86 (0.81–0.91)
Sogawa et al., 2016 [59]	Serum	C4BPA CA19-9 CEA C4BPA + CA19-9	66 PDAC, 40 HC, 20 CP	PDAC vs. HC + CP	67.3 71.2 34.6 86.4	95.4 95.4 95.4 95.4	0.86 (p < 0.001) 0.85 0.77 0.93
		C4BPA CA19-9 CEA	18 PDAC (stage I-II), 40 HC, 20 CP	PDAC stage I-II vs. HC + CP	50.0 22.2 22.2	95.4 95.4 95.4	0.91 (p < 0.001) 0.74 0.87
Yoneyama et al., 2016 [60]	Serum	CA19-9 IGFBP2 IGFBP3	38 PDAC (stage I-II), 65 HC	Stage I-II PDAC vs. HC	60.5 68.4 76.3	92.3 67.7 70.7	0.84 (0.75–0.93) 0.71 (0.60–0.81) 0.77 (0.67–0.86)
		CA19-9	55 PDAC (stage IA/ IB-IIA), 61HC	Stage IA/ IB-IIA vs. HC	71.0	61.0	0.74 (0.64–0.84)
Balasenthil et al., 2017 [61]	Plasma	TNC + TFP1 + CA19-9	55 PDAC (stage IA/ IB-IIA), 62 CP	Stage IA/ IB-IIA vs. CP	73.0	82.0	0.79 (0.70–0.87)
		CA19-9			71.0	44.0	0.69 (0.58–0.79)
		TNC + TFP1 + CA19-9			73.0	71.0	0.75 (0.65–0.84)
Yang et al., 2017 [62]	Plasma	EGFR EPCAM HER2 MUC1 GPC1 WNT2 GRP94 B7-H3	22 PDAC, 10 HC	TS: PDAC vs. HC	73	100	0.90 (0.79–1)
		EGFR + EPCAM + HER2 + MUC1			73	100	0.88 (0.77–0.99)
		EGFR + EPCAM + GPC1 + WNT2			59	90	0.72 (0.55–0.89)
		EGFR + EPCAM + MUC1 + GPC1 + WNT2			36	100	0.66 (0.48–0.84)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			55	60	0.48 (0.28–0.67)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			77	90	0.84 (0.71–0.96)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			73	70	0.73 (0.55–0.90)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			50	100	0.75 (0.58–0.93)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			91	100	0.99 (0.97–1)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			100	100	1.0
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			100	100	1.0
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			100	100	1.0
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			100	100	1.0
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			59	76	67 (51–81)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			45	95	70 (54–83)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			59	85	72 (56–85)
		EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2			36	90	63 (47–77)
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	82	52	67 (51–81)				
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	64	76	70 (54–83)				
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	55	71	63 (47–77)				
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	86	86	86 (72–95)				
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	82	90	86 (72–95)				
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	86	81	84 (69–93)				
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2	95	81	88 (75–96)				

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC		
Capello et al., 2017 [63]	Serum/ Plasma	CA19-9 TIMP1 + LRG1 + CA19-9 TIMP1 + LRG1 + CA19-9 (“OR” Rule) CA19-9	39 early stage PDAC, 82 HC	TS: early stage PDAC vs. HC	53.8	95.0	0.82 (0.74–0.91)		
		66.7			95.0	0.89 (0.82–0.96)			
					72.6	95.0	0.88 (0.81–0.96)		
					84.9	95.0	0.95 (0.92–0.98)		
		CA19-9 TIMP1 + LRG1 + CA19-9	73 early stage PDAC, 60 HC	VS: early stage PDAC vs. HC	84.9	95.0	0.96 (0.89–1.00)		
					28.8	95.0	0.82 (0.74–0.91)		
Hussein et al., 2017 [64]	Serum	miR-22-3p miR-642b-3p miR-885-5p CA19-9	35 PDAC (33 early stage, 2 late stage) 15 HC	PDAC vs. HC	97.1	93.3	0.94 (p < 0.001)		
					100	100	1.00 (p < 0.001)		
					100	100	1.00 (p < 0.001)		
					91.4	100	0.92 (p < 0.001)		
Kaur et al., 2017 [65]	Serum	MUC5AC CA19-9	70 PDAC (stage I or II), 43 CP, 35 HC, 30 BC	Early PDAC vs. HC	83.0	80.0	0.87 (0.79–0.95)		
					56.0	95.0	0.72 (0.59–0.84)		
					MUC5AC CA19-9	Early PDAC vs. BC	67.0	87.0	0.85 (0.76–0.93)
					48.0	89.0	0.71 (0.59–0.83)		
					MUC5AC CA19-9	Early PDAC vs. CP	83.0	77.0	0.84 (0.76–0.92)
48.0	86.0	0.62 (0.50–0.74)							
Kim et al., 2017 [66]	Plasma	CA19-9 (≥55) THBS2 (36ng/mL cut-off) CA19-9 + THBS2	58 (stage I-II, phase 2a), 80 HC	PDAC stage I or II vs. HC	89.0	70.0	0.88 (0.83–0.93)		
					79.0	43.0	0.61 (0.54–0.68)		
					83.0	83.0	0.91 (0.86–0.95)		
					69.0	100	0.85 (0.80–0.89)		
					33.0	96.0	0.83 (0.78–0.89)		
					74.1	96.3	0.95 (0.92–0.98)		
Lai et al., 2017 [67]	Plasma	CA19-9 miR-10b miR-21 miR-30c miR-106b miR-20a miR-181a miR-483 miR-let7a miR-122	29 PDAC, 6 HC	PDAC vs. HC	77.7	98.6	0.83 (0.79–0.97)		
					58.4	93.6	0.89 (0.85–0.92)		
					88.3	92.9	0.96 (0.94–0.98)		
					86.0	100.0	0.92 (p < 0.001)		
					100.0	100.0	1.00 (p < 0.001)		
					86.0	100.0	0.95 (p < 0.001)		
					100.0	100.0	1.00 (p < 0.001)		
					97.0	100.0	0.98 (p < 0.001)		
					93.0	100.0	0.99 (p < 0.001)		
					97.0	100.0	0.97 (p < 0.001)		
					66.0	67.0	0.67 (p = 0.20)		
					93.0	100.0	0.99 (p < 0.001)		
					100.0	67.0	0.89 (p = 0.003)		

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC		
Park et al., 2017 [68]	Serum	LRG1 + TTR + CA19-9	80 PDAC (50 stage I-II) (29 CA19-9 negative PDAC), 68 HC, 21 BPD, 52 Thyroid Ca, 52 Breast Ca, 45 Colorectal Ca)	PDAC vs. HC + BPC (n = 89)	82.5	92.1	0.93 (p < 0.01)		
		CA19-9		72.5	88.8	0.83			
		LRG1 + TTR + CA19-9		PDAC stage I-II vs. HC + BPC (n = 89)	76.0	92.1	0.91 (p < 0.01)		
		CA19-9		64.0	88.8	0.79			
		LRG1 + TTR + CA19-9		PDAC vs. Other Cancers (n = 149)	82.5	83.9	0.90 (p < 0.001)		
		CA19-9		72.5	87.9	0.80			
Schott et al., 2017 [69]	Serum	LRG1 + TTR + CA19-9	82 PDAC, 191 HC	PDAC vs. BPD	82.5	85.7	0.90		
		CA19-9		72.5	81.0	0.81			
Schott et al., 2017 [69]	Serum	LRG1 + TTR + CA19-9	60 PDAC (stage I-II), 191 HC	CA19-9 negative PDAC (n = 29) vs. HC + BPC	51.7	92.1	0.83 (p < 0.001)		
		CA19-9		24.1	88.8	0.52			
Schott et al., 2017 [69]	Serum	HYAL2 Methylation	82 PDAC, 191 HC	PDAC vs. HC	75.6	93.7	0.92 (0.88–0.96)		
				60 PDAC (stage I-II), 191 HC	PDAC stage I-II vs. HC	66.7	95.3	0.93 (0.89–0.98)	
Arasaradnam et al., 2018 [70]	Urine	Volatile organic compounds	4 PDAC stage I, 5 stage IIA, 35 stage IIB, 24 stage III, 12 stage IV, 81 HC	TS: PDAC vs. HC	0.91	0.83	0.92 (0.88–0.96)		
				VS: PDAC vs. HC	0.90	0.81	0.92 (0.85–0.98)		
				PDAC stage I-II vs. HC	0.91	0.78	0.89 (0.83–0.94)		
				PDAC stage I-II vs. PDAC stage III-IV	0.82	0.89	0.92 (0.86–0.97)		
Dong et al., 2018 [71]	Serum	CA19-9	30 PDAC (early stage), 68 PDAC (late stage), 32 BPC, 37 HC, 27 PDAC (CA19-9 negative)	TS: HC vs. early PDAC	96.7	83.8	0.94 (0.86–0.99)		
		POSTN			70.0	75.7	0.78 (0.66–0.87)		
		CA242			81.1	81.1	0.89 (0.79–0.95)		
		CA19-9 + POSTN			93.3	94.6	0.97 (0.90–1.00)		
		CA19-9 + CA242			90.0	94.6	0.96 (0.88–0.99)		
		POSTN+ CA242			83.3	86.5	0.90 (0.80–0.96)		
		CA19-9 + POSTN+ CA242			96.7	94.6	0.98 (0.90–1.00)		
		CA19-9			38 PDAC (early stage), 77 PDAC (late stage), 43 BPC, 37 HC, 29 PDAC (CA19-9 negative)	BPC vs. all PDAC	85.7	81.3	0.88 (0.82–0.93)
		POSTN					64.3	87.5	0.81 (0.74–0.88)
		CA242					58.1	87.5	0.78 (0.70–0.85)
		CA19-9 + POSTN					84.7	90.6	0.93 (0.88–0.97)
		CA19-9 + CA242					75.5	90.6	0.89 (0.83–0.94)
POSTN+ CA242	67.4	96.9	0.87 (0.80–0.92)						
CA19-9 + POSTN+ CA242	84.7	90.6	0.94 (0.88–0.97)						
CA19-9	38 PDAC (early stage), 77 PDAC (late stage), 43 BPC, 37 HC, 29 PDAC (CA19-9 negative)	BPC vs. early PDAC	86.7	81.3			0.88 (0.77–0.95)		
POSTN			53.3	87.5			0.74 (0.61–0.84)		
CA242			83.3	62.5			0.78 (0.66–0.88)		
CA19-9 + POSTN			96.7	75.0			0.90 (0.80–0.96)		
CA19-9 + CA242			90.0	78.1			0.90 (0.79–0.96)		
POSTN+ CA242			56.7	96.9	0.80 (0.68–0.89)				
CA19-9 + POSTN+ CA242			96.7	75.0	0.92 (0.82–0.97)				
CA19-9			38 PDAC (early stage), 77 PDAC (late stage), 43 BPC, 37 HC, 29 PDAC (CA19-9 negative)	VS: HC vs. early PDAC	86.8	94.6	0.94 (0.86–0.98)		
POSTN					63.2	78.4	0.78 (0.66–0.86)		
CA242					57.9	100	0.83 (0.73–0.91)		
CA19-9 + POSTN					86.8	97.3	0.95 (0.88–0.99)		
CA19-9 + CA242					86.8	97.3	0.97 (0.90–1.00)		
POSTN+ CA242	79.0	94.6			0.92 (0.84–0.97)				
CA19-9 + POSTN+ CA242	92.1	97.3			0.98 (0.92–1.00)				

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC
Dong et al., 2018 [71]	Serum	CA19-9		BPC vs. all PDAC	84.4	81.4	0.88 (0.82–0.93)
		POSTN			77.4	79.1	0.82 (0.76–0.88)
		CA242			60.0	93.0	0.79 (0.72–0.85)
		CA19-9 + POSTN			83.5	93.0	0.92 (0.87–0.96)
		CA19-9 + CA242			77.4	88.4	0.90 (0.84–0.94)
		POSTN+ CA242			84.4	83.7	0.89 (0.83–0.93)
		CA19-9 + POSTN+ CA242			80.0	97.7	0.93 (0.88–0.96)
		CA19-9			86.8	79.1	0.87 (0.78–0.93)
		POSTN			65.8	79.1	0.72 (0.61–0.82)
		CA242			57.9	93.0	0.77 (0.66–0.85)
		CA19-9 + POSTN			65.8	93.0	0.84 (0.75–0.92)
		CA19-9 + CA242			76.3	93.0	0.92 (0.83–0.97)
POSTN+ CA242	76.3	86.1	0.84 (0.74–0.91)				
CA19-9 + POSTN+ CA242	83.6	88.4	0.90 (0.81–0.96)				
Guo et al., 2018 [72]	Serum	SNHG15	171 PDAC, 59 HC	PDAC vs. HC	68.3	89.6	0.73 (p < 0.01)
Lewis et al., 2018 [73]	Whole blood, plasma, serum	GPC1 + CD63	20 PDAC 6 BPD	PDAC vs. BPD	81	70	0.79 (0.99–1.00)
Mellby et al., 2018 [74]	Plasma	Panel of 29 biomarkers	15 PDAC stage I, 75 stage II, 15 stage III, 38 stage IV	TS 2: PDAC stage I-II vs. HC	95	94	0.96 (0.94–0.98)
				VS (USA cohort): PDAC stage I-II vs. HC	93	95	0.96 (0.94–0.98)
Traeger et al., 2018 [75]	Serum	miRNA-205 CA19-9 miRNA-205 + CA19-9	47 PDAC, 16 CP, 5 IPMN, 17 BPC, 17 HC	PDAC vs. non-PDAC	0.643 0.810 0.867	0.684 0.768 0.933	0.70 (0.548–0.789) 0.79 (0.698–0.887) 0.89 (0.782–0.995)
Zhou et al., 2018 [76]	Serum	GPC1 CA19-9	156 PDAC, 20 BPT, 16 CP, 163 HC	PDAC vs. HC + BPT + CP	76.92 82.69	70.85 93.97	0.80 (0.749–0.841) 0.91 (0.868–0.947)
		GPC1 CA19-9		PDAC vs. HC	76.92 82.69	70.55 97.55	0.81 (0.763–0.856) 0.91 (0.875–0.953)
		GPC1 CA19-9		Early PDAC vs. HC + BPT + CP	68.06 79.17	70.85 93.97	0.76 (0.695–0.816) 0.88 (0.816–0.946)
		GPC1 CA19-9		Early PDAC vs. HC	68.06 79.17	70.55 97.55	0.77 (0.705–0.830) 0.89 (0.824–0.953)

Table 2. Cont.

Reference	Specimen Type	Biomarker	Clinical Setting	Subjects	Sensitivity (%)	Specificity (%)	AUC		
Berger et al., 2019 [77]	Plasma	CA19-9	52 PDAC, 15 IPMN, 32 CP	TS: PDAC vs. IPMN vs. CP	55	91	0.80		
		THBS2			41	96	0.73		
		cfDNA			32–86 <sup>1</sup>	70–100 <sup>1</sup>	0.90		
		CA19-9 + THBS2			73	91	0.87		
		THBS2 + CA19-9 + cfDNA			41–86 <sup>1</sup>	78–96 <sup>1</sup>	0.94		
		CA19-9			63	96	0.70		
Eissa et al., 2019 [78]	Plasma	THBS2	39 PDAC, 95 HC	VS: PDAC vs. IPMN vs. CP	50	96	0.63		
		cfDNA			43–80 <sup>1</sup>	79–96 <sup>1</sup>	0.81		
		CA19-9 + THBS2			80	96	0.78		
		THBS2 + CA19-9 + cfDNA			50–93 <sup>1</sup>	92–96 <sup>1</sup>	0.88		
		ADAMTS1			ADAMTS1	PDAC vs. HC	87.2	95.8	0.91 (0.77–0.90)
		BNC1					64.1	93.7	0.79 (0.63–0.78)
Fahrman et al., 2019 [79]	Plasma	ADAMTS1 and/or BNC1			97.4	91.6	0.95 (0.71–0.86)		
		AcSperm+ DAS + indole-derivative+ LysoPC(18:0) + LysoPC(20:3)	29 PDAC, 10 HC	TS: PDAC vs. HC	69.0	99.0	0.90 (0.818–0.989)		
		AcSperm+ DAS + indole-derivative+ LysoPC(18:0) + LysoPC(20:3)	39 Resectable PDAC, 82 HC	VS: PDAC vs. HC	66.7	43.3	0.89 (0.828–0.996)		
		Indole-derivative			23.1	11.3	0.73 (0.631–0.822)		
		LysoPC(18:0)			51.3	26.3	0.84 (0.764–0.920)		
		LysoPC(20:3)			48.7	11.3	0.84 (0.757–0.925)		
Yu et al., 2019 [80]	Plasma	AcSperm			33.3	27.5	0.76 (0.659–0.852)		
		DAS			51.3	27.5	0.80 (0.712–0.890)		
		d-signature: EV long RNA (FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1)	284 PDAC, 100 CP, 117 HC	PDAC vs. CP vs. HC d-signature with CA19-9	93.68	91.57	0.936 (0.889–0.983)		
		Takahashi et al., 2019 [81]	Serum	Circulating EV-encapsulated HULC	20 PDAC, 22 IPMN, 21 HC	PDAC vs. IPMN vs. HC	80	92.1	0.92
		Wei et al., 2019 [82]	Plasma	Vimetin-positive CTCs	100 PDAC, 16 IPMN, 30 HC	PDAC vs. IPMN vs. HC	65	100	0.968
Yang et al., 2020 [83]	Plasma	EV miRNAs and mRNAs, cfDNA, ccfDNA KRAS G12D/V/R mutations and CA19-9	30 CP + BPC, 49 PDAC, 57 HC	PDAC vs. non-PDAC vs. HC	88	95	0.95 (p = 0.103)		

Abbreviations: Aim: autoimmune diseases; BBO: benign biliary obstruction; BBP: benign biliary pathology; BCT: benign cystic tumor; BPD: benign pancreatic disease; BPT: benign pancreatic tumor; CC: cholangiocarcinoma; ccfDNA: circulating cell-free DNA; cf: circulating free; CP: chronic pancreatitis; CTC: circulating tumor cell; DC: discovery cohort; EV: extracellular vesicles; GC: gastric cancer; HC: healthy control; HCC: hepatocellular carcinoma; HULC: highly upregulated in liver cancer; IPMN: intraductal papillary mucinous neoplasm; PC: prospective cohort; PDAC: pancreatic ductal adenocarcinoma; TS: training set; VS: validation set. Note: <sup>1</sup> Depending on the concentration of cfDNA.



The studies summarized in Table 2 were all aimed at earlier PDAC detection; however, around 20% of them did not analyze their biomarkers in resectable stage I–II samples. While the paucity of earliest stage I samples is a recognized problem in the PDAC field, this was surprising, considering the critical importance of diagnostic stage shift. Selection of the relevant control population is also of the essence, as PDAC is an uncommon cancer, which dictates the need to assess the putative biomarkers in high-risk groups [1,84,85], a criterion which was not satisfied in 20% of the studies. It also requires the high accuracy of any potential future biomarker assay with at least 88% SN and 85% SP if the test is to be cost-effective [86].

A third of the reviewed studies did not include a comparison of their biomarkers to CA19-9, which was unexpected considering that CA19-9 is the most commonly measured biomarker in PDAC patients. Very few biomarkers were conclusively superior to CA19-9 and in the majority of studies where their combination was tested, the accuracy of PDAC detection was superior to either biomarker alone. For example, Dong et al. [71] described the panel of serum biomarkers comprising CA19-9, POSTN and CA242, which was superior to CA19-9 alone in differentiating between PDAC and both healthy controls (AUC of 0.98, 92.1% SN and 97.3% SP) and benign pancreatic conditions (AUC of 0.93, 80% SN and 97.7% SP), albeit with somewhat lower AUC of 0.90 and a decrease in SP to 88% in resectable PDAC. In the study of Berger et al. [77], CA19-9 combined with THBS2 and cfDNA in PDAC vs. non-PDAC patients showed an increase in AUC from 0.70 to 0.78, with an increased SN and SP of 80% and 96%, respectively. A study by Fahrman et al. [79] combined a five-metabolite panel (acetylspermidine, diacetylspermine, an indole-derivative and two lysophosphatidylcholines) with a previously validated protein panel comprising CA19-9, TIMP1 and LRG1, achieving AUC of 0.924 (95% CI 0.864–0.983). Recently, another panel (FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1) obtained by plasma extracellular vesicle long RNA profiling (d-signature), successfully differentiated PDAC from CP and healthy controls with AUC of 0.936, and both SN and SP > 90%; furthermore, when combined with CA19-9, the signature showed improved AUC of 0.964 (95% CI: 0.943–0.984) [80]. Traeger et al., reported that miRNA-205 combined with CA19-9 resulted in higher SN and SP in comparison of PDAC vs. benign specimens (86.7% SN and 93.3% SP) than either of the biomarkers alone [75].

The absolute SN and SP values for PDAC detection using glypican-1 (GPC1) in circulating exosomes when PDAC samples were compared to healthy and benign samples was reported by Melo et al. [54]. However, several subsequent studies failed to support these findings [62,73,87,88], while Zhou et al. [76] demonstrated that combining GPC1 and CA19-9 showed 92.31% SN at 65.83% SP for distinguishing healthy, chronic pancreatitis and benign pancreatic tumors from PDAC. Regardless of the underlying reasons, these conflicting results highlight the critical importance of independent validation of any proposed biomarkers.

The above study [54] and the more recent studies indicate the “expansion” of the biomarker field, moving from the “traditional” DNA, RNA and protein biomarkers to novel, versatile analytes and their combinations, such as non-coding RNAs, epigenetic markers, lipids and metabolites, as well as circulating tumor cells and extracellular vesicles (EV) [88]. For example, Yang et al. [83] performed a multi-parametric analysis of blood tumor-associated EV miRNA and mRNA, circulating cell-free DNA concentration and KRAS G12D/V/R mutations with CA19-9, and demonstrated their higher accuracy for PDAC staging (84%) than imaging alone (accuracy = 64%;  $P < 0.05$ ). Furthermore, recent advances in computer science, machine learning and artificial intelligence (AI) have given rise to the emerging field of bioinformatics and computational biology which allow analyses of large collections of biological data [89]. While AI was mostly utilized for the prediction of risk/diagnosis based on health records or abdominal imaging [1,90,91], it also shows a great potential for in silico discovery of putative novel biomarkers. For example, Khatri and Bhasin [92] used transcriptomics-based meta-analysis of tissue and blood samples combined with machine learning to identify a nine-gene panel (IFI27, ITGB5, CTSD, EFNA4,

GGH, PLBD1, HTATIP2, IL1R2 and CTSA) that differentiated PDAC and healthy controls with 92% SN and 90% SP. Moreover, this panel also discriminated PDAC from chronic pancreatitis and early precursor lesions in non-malignant tissue and peripheral blood. Chung et al. [93] used probe electrospray ionization mass spectrometry (PESI-MS) and a machine learning approach to analyze peripheral blood samples and achieved an accuracy of 92.1% in healthy vs. PDAC (90.8% SN, 91.7% SP). The combination of PESI-MS profiles with age and CA19-9 increased the accuracy for detection of stage I and II PDAC to 92.9% (81.2% SN, 96.8% SP) [40]. This demonstrates that the access to richly annotated patients' health records will enable the construction of novel PDAC prediction tools such as the one developed by Muhammad et al. [90]. Combining such prediction tools with biofluid biomarkers now opens up promising new avenues and likely a fruitful approach to identify asymptomatic patients at increased risk of developing PDAC.

Very few studies explored the effectiveness of their proposed biomarkers in pre-diagnostic samples from asymptomatic patients. Although such samples are not readily available, these studies are essential for determining how early in the latency period the biomarkers can be detected [40,47,94–101]. Nolen et al. [47] interrogated the large prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial serum samples to detect eight biomarkers: CEA-related cell adhesion molecule 1 (CEACAM1) and prolactin (PRL) were detectable up to 35 months before PDAC diagnosis; CA19-9, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE) and beta-human chorionic gonadotropin (b-HCG) up to 24 months; and CA125 and interleukin 8 (IL-8) up to 12 months prior PDAC diagnosis. In the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) serum samples, a decrease in circulating TSP-1 levels up to 24 months prior to PDAC diagnosis was described by Jenkinson et al. [97], and O'Brien et al. demonstrated that CA19-9 could be detected in such pre-diagnostic PDAC samples with 95% SP and 68% SN up to 1 year and 53% SN up to 2 years prior to PDAC diagnosis [98]. A three-biomarker panel comprising Erb-B2 receptor tyrosine kinase 2 (ERBB2), estrogen receptor 1 (ESR1) and tenascin C (TNC) was analyzed in 87 pre-diagnostic plasma samples from Women's Health Initiative (WHI) collected up to 4 years before diagnosis and achieved AUC of 0.71 when combined with CA19-9 [100]. Recently, the analysis of 1196 proteins in longitudinal plasma samples from the Institute for Systems Biology's 100K Wellness project identified several markers, including three that were observed in PDAC: CEA cell adhesion molecule 5 (CEACAM5) was expressed at high levels 26.5 months pre-diagnosis, while calcitonin related polypeptide alpha (CALCA) and delta1 like homolog (DLK1) were predating PDAC diagnosis for around 17 months [101]. More exciting projects such as this are needed and should be actively encouraged.

While performing this review, we encountered a number of hurdles, particularly noticeable in the way the studies were reported. Easier reviewing of published resources would be facilitated, and the extraction of the relevant information simplified, if a consensus set of standards for the reporting of biomarker studies were utilized. In addition to QUADAS-2, several of such recommendations and guidelines exist: BRISQ (Biospecimen Reporting for Improved Study Quality) [102] provides recommendations for reporting details about the interrogated biospecimens; the Standards for Reporting of Diagnostic Accuracy Studies (STARD) [103] was developed to improve the completeness and transparency of the reports; and Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) [104] and Consolidated Standards of Reporting Trials (CONSORT Statement) [105] are used to improve the overall quality of tumor markers in the prognostic studies and randomized trials [104,105]. The latter is the final step in establishing the clinical utility of the biomarker, i.e., increased survival due to earlier diagnosis achieved by biomarker testing. Interestingly, only studies published in high-impact factors journals followed any of these recommendations [49,54,66,74,80].

In addition to the standardized way of reporting, a standardized pathway for early detection and diagnosis is also needed. Such pathway has recently been summarized in the updated Cancer Research UK (CRUK) roadmap, which aims to consolidate the

current diverse and fragmented research activities, in line with the future vision to detect 75% of cancers at stage I-II by 2028 [106]. A roadmap also illustrates a long way from biomarker discovery to its implementation, with a number of hurdles encountered at every step in biomarker pipeline, from initial biomarker discovery, its quantification, verification and assay optimization to finally biomarker validation and commercialization, as comprehensively discussed previously [107–109]. While biomarker discovery is usually well funded and results straightforward to report, validation, which is a necessary step prior to commercialization, is time-consuming and expensive process, with scarce funding available. The transition from discovery to the clinical utility of any biomarker is therefore a cumbersome process, akin to the implementation of novel therapeutic [110].

It is not surprising thus that, despite a large number of candidate biomarkers, very few are close to clinical implementation. Based on the accuracy of 95% of serum biomarker signature published by Mellby et al. [74] and using their proprietary antibody platform, Immunovia is now developing the commercial assay IMMRay™ PanCan-d, which is currently being further validated in the prospective studies [111]. Our urinary biomarker panel comprising REG1B, LYVE1, TFF1 and the affiliated PancRISK score [112,113] are now being validated in a prospective study UroPanc [114]. A multi-analyte blood test that simultaneously evaluates the levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA, CancerSEEK®, screens for eight common cancers, including PDAC [115], and has already been commercialized. GRAIL is advocating its own Galleri test, which is based on cfDNA methylation signal and can detect over 50 different cancers [116]. Both platforms, however, suffer from lower SN in detecting stage I cancers, and there is a legitimate concern that the tests might be less specific in real-world conditions, where comorbidities may increase the risk of a false-positive result [117].

#### 4. Conclusions

In summary, our systematic review demonstrates the current progress in the biomarker field and highlights several promising non-invasive PDAC biomarkers. Most of these, however, still require further validation prior to being deemed appropriate for translation into the clinical setting. All future studies should aim to improve methodological quality and the way of reporting. Novel biomarkers that have shown promising results should be further investigated on a larger number of specimens, as well as in a pre-diagnostic and prospective setting, to further demonstrate their real clinical utility in earlier detection of pancreatic adenocarcinoma.

**Author Contributions:** Conceptualization, V.S., G.B. and T.C.-J.; methodology, G.B., V.S. and T.C.-J.; writing and editing, G.B., V.S., D.J. and T.C.-J.; and supervision, T.C.-J. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### Appendix A

**Table A1.** Graphical summary of the QUADAS-2 scores for each of the 49 studies.

Nr.	Study	Risk of Bias			Applicability Concerns			Score
		Patient Selection	Index Test	Reference Standard	Patient Selection	Index Test	Reference Standard	
1	Gold et al., 2010 [37]	☺	?	?	☺	☺	☺	Low
2	Joergensen et al., 2010 [38]	☺	?	☺	☺	☺	☺	Low
3	Marten et al., 2010 [39]	☹	?	☺	☹	?	☺	High
4	Brand et al., 2011 [17]	☺	☺	?	☹	☺	☺	Low

Table A1. Cont.

Nr.	Study	Risk of Bias			Applicability Concerns			Score
		Patient Selection	Index Test	Reference Standard	Patient Selection	Index Test	Reference Standard	
5	Park et al., 2012 [21]							Low
6	Capello et al., 2013 [40]							Low
7	Gold et al., 2013 [41]							Low
8	Kobayashi et al., 2013 [42]							Low
9	Li et al., 2013 [43]							Low
10	Zhao et al., 2013 [44]							High
11	Chung et al., 2014 [45]							Low
12	Lee et al., 2014 [46]							Low
13	Nolen et al., 2014 [47]							Low
14	Ren et al., 2014 [48]							Low
15	Schultz et al., 2014 [49]							Low
16	Yang et al., 2014 [50]							High
17	Zhang et al., 2014 [51]							Low
18	Debernardi et al., 2015 [52]							High
19	Han et al., 2015 [53]							Low
20	Melo et al., 2015 [54]							Low
21	Radon et al., 2015 [55]							Low
22	Ankeny et al., 2016 [56]							High
23	Guo et al., 2016 [57]							Low
24	Henriksen et al., 2016 [58]							Low
25	Sogawa et al., 2016 [59]							Low
26	Yoneyama et al., 2016 [60]							Low
27	Balasesenthil et al., 2017 [61]							Low
28	Yang et al., 2017 [62]							Low
29	Capello et al., 2017 [63]							Low
30	Hussein et al., 2017 [64]							High
31	Kaur et al., 2017 [65]							Low
32	Kim et al., 2017 [66]							Low
33	Lai et al., 2017 [67]							High
34	Park et al., 2017 [68]							Low
35	Schott et al., 2017 [69]							High
36	Arasaradnam et al., 2018 [70]							High
37	Dong et al., 2018 [71]							Low
38	Guo et al., 2018 [72]							High

Table A1. Cont.

Nr.	Study	Risk of Bias			Applicability Concerns			Score
		Patient Selection	Index Test	Reference Standard	Patient Selection	Index Test	Reference Standard	
39	Mellby et al., 2018 [74]	☺	?	☺	☺	☺	☺	Low
40	Traeger et al., 2018 [75]	☺	☹	☺	☺	☺	☺	Low
41	Zhou et al., 2018 [76]	☺	☹	☺	☹	?	☺	High
42	Berger et al., 2019 [77]	☺	☺	☺	☺	☺	☺	Low
43	Eissa et al., 2019 [78]	☺	☹	?	☺	☺	☺	Low
44	Fahrmann et al., 2019 [79]	☺	☺	☺	☺	☺	☺	Low
45	Lewis et al., 2019 [73]	☺	?	?	☹	?	☺	High
46	Yu et al., 2019 [80]	☺	☹	☺	☺	☺	☺	Low
47	Takahashi et al., 2019 [81]	☺	☹	?	☺	?	☺	High
48	Wei et al., 2019 [82]	☺	☹	☺	☺	?	☺	Low
49	Yang et al., 2020 [83]	☺	☺	☺	☺	?	☺	Low

☺ Low Risk; ☹ High Risk; ? Unclear Risk.

## References

- Pereira, S.P.; Oldfield, L.; Ney, A.; Hart, P.A.; Keane, M.G.; Pandol, S.J.; Li, D.; Greenhalf, W.; Jeon, C.Y.; Koay, E.J.; et al. Early detection of pancreatic cancer. *Lancet Gastroenterol. Hepatol.* **2020**, *5*, 698–710. [CrossRef]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. *CA Cancer J. Clin.* **2020**, *70*, 7–30. [CrossRef]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2018**, *68*, 394–424. [CrossRef] [PubMed]
- da Costa, W.L., Jr.; Oluyomi, A.O.; Thrift, A.P. Trends in the Incidence of Pancreatic Adenocarcinoma in All 50 United States Examined Through an Age-Period-Cohort Analysis. *JNCI Cancer Spectr.* **2020**, *4*, pkaa033. [CrossRef]
- Rawla, P.; Sunkara, T.; Gaduputi, V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J. Oncol.* **2019**, *10*, 10–27. [CrossRef]
- Lin, Q.J.; Yang, F.; Jin, C.; Fu, D.L. Current status and progress of pancreatic cancer in China. *World J. Gastroenterol.* **2015**, *21*, 7988–8003. [CrossRef]
- Shen, G.Q.; Aleassa, E.M.; Walsh, R.M.; Morris-Stiff, G. Next-Generation Sequencing in Pancreatic Cancer. *Pancreas* **2019**, *48*, 739–748. [CrossRef] [PubMed]
- Bortesi, L.; Pesci, A.; Bogina, G.; Castelli, P.; Zamboni, G. Ductal Adenocarcinoma of the Pancreas. *Surg. Pathol. Clin.* **2011**, *4*, 487–521. [CrossRef]
- CancerResearchUK. Pancreatic Cancer Statistics 2015–2017. Available online: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer> (accessed on 15 July 2020).
- Pancreatic Cancer UK. Pancreatic Cancer Statistics. Available online: <https://www.pancreaticcancer.org.uk/what-we-do/media-centre/pancreatic-cancer-statistics> (accessed on 2 July 2020).
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. *CA Cancer J. Clin.* **2018**, *68*, 7–30. [CrossRef] [PubMed]
- Huang, L.; Jansen, L.; Balavarca, Y.; Molina-Montes, E.; Babaei, M.; van der Geest, L.; Lemmens, V.; Van Eycken, L.; De Schutter, H.; Johannesen, T.B.; et al. Resection of pancreatic cancer in Europe and USA: An international large-scale study highlighting large variations. *Gut* **2019**, *68*, 130. [CrossRef]
- Shimizu, Y.; Yasui, K.; Matsueda, K.; Yanagisawa, A.; Yamao, K. Small carcinoma of the pancreas is curable: New computed tomography finding, pathological study and postoperative results from a single institute. *J. Gastroenterol. Hepatol.* **2005**, *20*, 1591–1594. [CrossRef]
- Ishikawa, O.; Ohigashi, H.; Imaoka, S.; Nakaizumi, A.; Uehara, H.; Kitamura, T.; Kuroda, C. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—Collective review of Japanese case reports. *Hepatogastroenterology* **1999**, *46*, 8–15.
- Yachida, S.; Jones, S.; Bozic, I.; Antal, T.; Leary, R.; Fu, B.; Kamiyama, M.; Hruban, R.H.; Eshleman, J.R.; Nowak, M.A.; et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* **2010**, *467*, 1114–1117. [CrossRef]
- Ghaneh, P.; Costello, E.; Neoptolemos, J.P. Biology and management of pancreatic cancer. *Gut* **2007**, *56*, 1134–1152. [CrossRef]



17. Brand, R.E.; Nolen, B.M.; Zeh, H.J.; Allen, P.J.; Eloubeidi, M.A.; Goldberg, M.; Elton, E.; Arnoletti, J.P.; Christein, J.D.; Vickers, S.M.; et al. Serum biomarker panels for the detection of pancreatic cancer. *Clin. Cancer Res.* **2011**, *17*, 805–816. [CrossRef]
18. Chan, A.; Diamandis, E.P.; Blasutig, I.M. Strategies for discovering novel pancreatic cancer biomarkers. *J. Proteom.* **2013**, *81*, 126–134. [CrossRef]
19. Tempero, M.A.; Uchida, E.; Takasaki, H.; Burnett, D.A.; Steplewski, Z.; Pour, P.M. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. *Cancer Res.* **1987**, *47*, 5501–5503.
20. FDA. FDA 510K Summary. Available online: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf2/K020566.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf2/K020566.pdf) (accessed on 20 February 2021).
21. Park, H.-D.; Kang, E.-S.; Kim, J.-W.; Lee, K.-T.; Lee, K.H.; Park, Y.S.; Park, J.-O.; Lee, J.; Heo, J.S.; Choi, S.H.; et al. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. *Proteomics* **2012**, *12*, 3590–3597. [CrossRef] [PubMed]
22. Ritts, R.E.; Pitt, H.A. CA 19-9 in pancreatic cancer. *Surg. Oncol. Clin. N. Am.* **1998**, *7*, 93–101. [CrossRef]
23. Duffy, M.J.; van Dalen, A.; Haglund, C.; Hansson, L.; Klapdor, R.; Lamerz, R.; Nilsson, O.; Sturgeon, C.; Topolcan, O. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. *Eur. J. Cancer* **2003**, *39*, 718–727. [CrossRef]
24. Ballehaninna, U.K.; Chamberlain, R.S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. *J. Gastrointest. Oncol.* **2012**, *3*, 105–119. [CrossRef]
25. Passerini, R.; Cassatella, M.C.; Boveri, S.; Salvatici, M.; Radice, D.; Zorzino, L.; Galli, C.; Sandri, M.T. The pitfalls of CA19-9: Routine testing and comparison of two automated immunoassays in a reference oncology center. *Am. J. Clin. Pathol.* **2012**, *138*, 281–287. [CrossRef]
26. Duffy, M.J.; Sturgeon, C.; Lamerz, R.; Haglund, C.; Holubec, V.L.; Klapdor, R.; Nicolini, A.; Topolcan, O.; Heinemann, V. Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report. *Ann. Oncol.* **2010**, *21*, 441–447. [CrossRef]
27. Herlyn, M.; Steplewski, Z.; Herlyn, D.; Koprowski, H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. *Proc. Natl. Acad. Sci. USA* **1979**, *76*, 1438–1442. [CrossRef] [PubMed]
28. Hotakainen, K.; Tanner, P.; Alfthan, H.; Haglund, C.; Stenman, U.H. Comparison of three immunoassays for CA 19-9. *Clin. Chim. Acta* **2009**, *400*, 123–127. [CrossRef] [PubMed]
29. Steinberg, W. The clinical utility of the CA 19-9 tumor-associated antigen. *Am. J. Gastroenterol.* **1990**, *85*, 350–355.
30. Stern, P.; Friedecky, B.; Bartos, V.; Bezdicikova, D.; Vavrova, J.; Uhrova, J.; Rozprimova, L.; Zima, T.; Palicka, V. Comparison of different immunoassays for CA 19-9. *Clin. Chem. Lab. Med.* **2001**, *39*, 1278–1282. [CrossRef]
31. Goh, S.K.; Gold, G.; Christophi, C.; Muralidharan, V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: A mini review for surgeons. *ANZ J. Surg.* **2017**, *87*, 987–992. [CrossRef]
32. Jain, K.K. *The Handbook of Biomarkers*; Humana Press: Totowa, NJ, USA, 2010.
33. Young, M.R.; Wagner, P.D.; Ghosh, S.; Rinaudo, J.A.; Baker, S.G.; Zaret, K.S.; Goggins, M.; Srivastava, S. Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop. *Pancreas* **2018**, *47*, 135–141. [CrossRef]
34. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* **2009**, *6*, e1000097. [CrossRef]
35. Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann. Intern. Med.* **2011**, *155*, 529–536. [CrossRef]
36. Whiting, P.; Rutjes, A.W.; Reitsma, J.B.; Bossuyt, P.M.; Kleijnen, J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med. Res. Methodol.* **2003**, *3*, 25. [CrossRef]
37. Gold, D.V.; Goggins, M.; Modrak, D.E.; Newsome, G.; Liu, M.; Shi, C.; Hruban, R.H.; Goldenberg, D.M. Detection of early-stage pancreatic adenocarcinoma. *Cancer Epidemiol. Biomark. Prev.* **2010**, *19*, 2786–2794. [CrossRef] [PubMed]
38. Joergensen, M.T.; Brunner, N.; De Muckadell, O.B.S. Comparison of Circulating MMP-9, TIMP-1 and CA19-9 in the Detection of Pancreatic Cancer. *Anticancer Res.* **2010**, *30*, 587–592. [PubMed]
39. Marten, A.; Buchler, M.W.; Werft, W.; Wentz, M.N.; Kirschfink, M.; Schmidt, J. Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology. *J. Immunother.* **2010**, *33*, 219–224. [CrossRef]
40. Capello, M.; Cappello, P.; Linty, F.C.; Chiarle, R.; Sperduti, I.; Novarino, A.; Salacone, P.; Mandili, G.; Naccarati, A.; Sacerdote, C.; et al. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. *J. Hematol. Oncol.* **2013**, *6*, 67. [CrossRef] [PubMed]
41. Gold, D.V.; Gaedcke, J.; Ghadimi, B.M.; Goggins, M.; Hruban, R.H.; Liu, M.L.; Newsome, G.; Goldenberg, D.M. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. *Cancer* **2013**, *119*, 522–528. [CrossRef]
42. Kobayashi, T.; Nishiumi, S.; Ikeda, A.; Yoshie, T.; Sakai, A.; Matsubara, A.; Izumi, Y.; Tsumura, H.; Tsuda, M.; Nishisaki, H.; et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. *Cancer Epidemiol. Biomark. Prev.* **2013**, *22*, 571–579. [CrossRef]

43. Li, A.; Yu, J.; Kim, H.; Wolfgang, C.L.; Canto, M.I.; Hruban, R.H.; Goggins, M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. *Clin. Cancer Res.* **2013**, *19*, 3600–3610. [[CrossRef](#)]
44. Zhao, C.; Zhang, J.; Zhang, S.; Yu, D.; Chen, Y.; Liu, Q.; Shi, M.; Ni, C.; Zhu, M. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. *Oncol. Rep.* **2013**, *30*, 276–284. [[CrossRef](#)] [[PubMed](#)]
45. Chung, H.W.; Lim, J.B. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. *J. Transl. Med.* **2014**, *12*, 102. [[CrossRef](#)] [[PubMed](#)]
46. Lee, M.J.; Na, K.; Jeong, S.K.; Lim, J.S.; Kim, S.A.; Song, S.Y.; Kim, H.; Hancock, W.S.; Paik, Y.K. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. *J. Proteome Res.* **2014**, *13*, 4878–4888. [[CrossRef](#)] [[PubMed](#)]
47. Nolen, B.M.; Brand, R.E.; Prosser, D.; Velikokhatnaya, L.; Allen, P.J.; Zeh, H.J.; Grizzle, W.E.; Huang, Y.; Lomakin, A.; Lokshin, A.E. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. *PLoS ONE* **2014**, *9*, e94928. [[CrossRef](#)] [[PubMed](#)]
48. Ren, C.; Chen, Y.; Han, C.; Fu, D.; Chen, H. Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer. *Tumour Biol.* **2014**, *35*, 11467–11472. [[CrossRef](#)]
49. Schultz, N.A.; Dehlendorff, C.; Jensen, B.V.; Bjerregaard, J.K.; Nielsen, K.R.; Bojesen, S.E.; Calatayud, D.; Nielsen, S.E.; Yilmaz, M.; Holländer, N.H.; et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. *JAMA* **2014**, *311*, 392–404. [[CrossRef](#)] [[PubMed](#)]
50. Yang, J.Y.; Sun, Y.W.; Liu, D.J.; Zhang, J.F.; Li, J.; Hua, R. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. *Am. J. Cancer Res.* **2014**, *4*, 663–673. [[PubMed](#)]
51. Zhang, P.J.; Zou, M.; Wen, X.Y.; Gu, F.; Li, J.; Liu, G.X.; Dong, J.X.; Deng, X.X.; Gao, J.; Li, X.L.; et al. Development of serum parameters panels for the early detection of pancreatic cancer. *Int. J. Cancer* **2014**, *134*, 2646–2655. [[CrossRef](#)]
52. Debernardi, S.; Massat, N.J.; Radon, T.P.; Sangaralingam, A.; Banissi, A.; Ennis, D.P.; Dowe, T.; Chelala, C.; Pereira, S.P.; Kocher, H.M.; et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. *Am. J. Cancer Res.* **2015**, *5*, 3455–3466.
53. Han, S.X.; Zhou, X.; Sui, X.; He, C.C.; Cai, M.J.; Ma, J.L.; Zhang, Y.Y.; Zhou, C.Y.; Ma, C.X.; Varela-Ramirez, A.; et al. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. *Oncotarget* **2015**, *6*, 19907–19917. [[CrossRef](#)]
54. Melo, S.A.; Luecke, L.B.; Kahlert, C.; Fernandez, A.F.; Gammon, S.T.; Kaye, J.; LeBleu, V.S.; Mittendorf, E.A.; Weitz, J.; Rahbari, N.; et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* **2015**, *523*, 177–182. [[CrossRef](#)]
55. Radon, T.P.; Massat, N.J.; Jones, R.; Alrawashdeh, W.; Dumartin, L.; Ennis, D.; Duffy, S.W.; Kocher, H.M.; Pereira, S.P.; Guarner, L.; et al. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. *Clin. Cancer Res.* **2015**, *21*, 3512–3521. [[CrossRef](#)] [[PubMed](#)]
56. Ankeny, J.S.; Court, C.M.; Hou, S.; Li, Q.; Song, M.; Wu, D.; Chen, J.F.; Lee, T.; Lin, M.; Sho, S.; et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. *Br. J. Cancer* **2016**, *114*, 1367–1375. [[CrossRef](#)]
57. Guo, X.; Lv, X.; Fang, C.; Wang, F.; Wang, D.; Zhao, J.; Ma, Y.; Xue, Y.; Bai, Q.; Yao, X.; et al. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. *Int. J. Cancer* **2016**, *139*, 1821–1829. [[CrossRef](#)]
58. Henriksen, S.D.; Madsen, P.H.; Larsen, A.C.; Johansen, M.B.; Drewes, A.M.; Pedersen, I.S.; Krarup, H.; Thorlacius-Ussing, O. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. *Clin. Epigenetics* **2016**, *8*, 1–12. [[CrossRef](#)]
59. Sogawa, K.; Takano, S.; Iida, F.; Satoh, M.; Tsuchida, S.; Kawashima, Y.; Yoshitomi, H.; Sanda, A.; Kodera, Y.; Takizawa, H.; et al. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein  $\alpha$ -chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. *Br. J. Cancer* **2016**, *115*, 949–956. [[CrossRef](#)]
60. Yoneyama, T.; Ohtsuki, S.; Honda, K.; Kobayashi, M.; Iwasaki, M.; Uchida, Y.; Okusaka, T.; Nakamori, S.; Shimahara, M.; Ueno, T.; et al. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. *PLoS ONE* **2016**, *11*, e0161009. [[CrossRef](#)] [[PubMed](#)]
61. Balasenthil, S.; Huang, Y.; Liu, S.; Marsh, T.; Chen, J.; Stass, S.A.; KuKuruga, D.; Brand, R.; Chen, N.; Frazier, M.L.; et al. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. *J. Natl. Cancer Inst.* **2017**, *109*. [[CrossRef](#)] [[PubMed](#)]
62. Yang, K.S.; Im, H.; Hong, S.; Pergolini, I.; del Castillo, A.F.; Wang, R.; Clardy, S.; Huang, C.-H.; Pille, C.; Ferrone, S.; et al. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. *Sci. Transl. Med.* **2017**, *9*, eaal3226. [[CrossRef](#)] [[PubMed](#)]
63. Capello, M.; Bantis, L.; Scelo, G.; Zhao, Y.; Dhillon, D.; Wang, H.; Abbruzzese, J.; Maitra, A.; Tempero, M.; Brand, R.; et al. Sequential validation of bloodbased protein biomarker candidates for early-stage pancreatic cancer. In Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, AACR 2016, New Orleans, LA, USA, 16–20 April 2016; Volume 76.
64. Hussein, N.A.; Kholy, Z.A.; Anwar, M.M.; Ahmad, M.A.; Ahmad, S.M. Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer. *J. Cancer Res. Clin. Oncol.* **2017**, *143*, 83–93. [[CrossRef](#)]



65. Kaur, S.; Smith, L.; Patel, A.; Menning, M.; Watley, D.; Malik, S.; Krishn, S.; Mallya, K.; Aithal, A.; Sasson, A.; et al. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. *Am. J. Gastroenterol.* **2017**, *112*, 172–183. [[CrossRef](#)] [[PubMed](#)]
66. Kim, J.; Bamlet, W.R.; Oberg, A.L.; Chaffee, K.G.; Donahue, G.; Cao, X.J.; Chari, S.; Garcia, B.A.; Petersen, G.M.; Zaret, K.S. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. *Sci. Transl. Med.* **2017**, *9*, eaah5583. [[CrossRef](#)] [[PubMed](#)]
67. Lai, X.Y.; Wang, M.; McElyea, S.D.; Sherman, S.; House, M.; Korc, M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. *Cancer Lett.* **2017**, *393*, 86–93. [[CrossRef](#)]
68. Park, J.; Choi, Y.; Namkung, J.; Yi, S.G.; Kim, H.; Yu, J.; Kim, Y.; Kwon, M.S.; Kwon, W.; Oh, D.Y.; et al. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. *Oncotarget* **2017**, *8*, 93117–93130. [[CrossRef](#)]
69. Schott, S.; Yang, R.X.; Stocker, S.; Canzian, F.; Giese, N.; Bugert, P.; Bergmann, F.; Strobel, O.; Hackert, T.; Sohn, C.; et al. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer—a case control study. *Oncotarget* **2017**, *8*, 67614–67625. [[CrossRef](#)] [[PubMed](#)]
70. Arasaradnam, R.P.; Wicaksono, A.; O'Brien, H.; Kocher, H.M.; Covington, J.A.; Crnogorac-Jurcevic, T. Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine. *Gastroenterology* **2018**, *154*, 485–487.e481. [[CrossRef](#)] [[PubMed](#)]
71. Dong, D.; Jia, L.; Zhang, L.; Ma, N.; Zhang, A.; Zhou, Y.; Ren, L. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. *Cancer Sci.* **2018**, *109*, 2841–2851. [[CrossRef](#)]
72. Guo, X.B.; Yin, H.S.; Wang, J.Y. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma. *Eur. Rev. Med. Pharm. Sci.* **2018**, *22*, 5892–5898. [[CrossRef](#)]
73. Lewis, J.M.; Vyas, A.D.; Qiu, Y.; Messer, K.S.; White, R.; Heller, M.J. Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. *ACS Nano* **2018**, *12*, 3311–3320. [[CrossRef](#)]
74. Mellby, L.D.; Nyberg, A.P.; Johansen, J.S.; Wingren, C.; Nordestgaard, B.G.; Bojesen, S.E.; Mitchell, B.L.; Sheppard, B.C.; Sears, R.C.; Borrebaeck, C.A.K. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. *J. Clin. Oncol.* **2018**, *36*, 2887–2894. [[CrossRef](#)] [[PubMed](#)]
75. Michael Traeger, M.; Rehkaemper, J.; Ullerich, H.; Steinestel, K.; Wardelmann, E.; Senninger, N.; Abdallah Dhayat, S. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. *J. Cancer Res. Clin. Oncol.* **2018**, *144*, 2419–2431. [[CrossRef](#)]
76. Zhou, C.Y.; Dong, Y.P.; Sun, X.; Sui, X.; Zhu, H.; Zhao, Y.Q.; Zhang, Y.Y.; Mason, C.; Zhu, Q.; Han, S.X. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. *Cancer Med.* **2018**, *7*, 5525–5533. [[CrossRef](#)]
77. Berger, A.W.; Schwerdel, D.; Reinacher-Schick, A.; Uhl, W.; Algül, H.; Friess, H.; Janssen, K.-P.; König, A.; Ghadimi, M.; Gallmeier, E.; et al. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. *Theranostics* **2019**, *9*, 1280–1287. [[CrossRef](#)]
78. Eissa, M.A.L.; Lerner, L.; Abdelfatah, E.; Shankar, N.; Canner, J.K.; Hasan, N.M.; Yaghoobi, V.; Huang, B.; Kerner, Z.; Takaesu, F.; et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. *Clin. Epigenetics* **2019**, *11*, 59. [[CrossRef](#)] [[PubMed](#)]
79. Fahrman, J.F.; Bantis, L.E.; Capello, M.; Scelo, G.; Dennison, J.B.; Patel, N.; Murage, E.; Vykoukal, J.; Kundnani, D.L.; Foretova, L.; et al. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. *J. Natl. Cancer Inst.* **2019**, *111*, 372–379. [[CrossRef](#)]
80. Yu, S.; Li, Y.; Liao, Z.; Wang, Z.; Wang, Z.; Li, Y.; Qian, L.; Zhao, J.; Zong, H.; Kang, B.; et al. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. *Gut* **2020**, *69*, 540–550. [[CrossRef](#)]
81. Takahashi, K.; Ota, Y.; Kogure, T.; Suzuki, Y.; Iwamoto, H.; Yamakita, K.; Kitano, Y.; Fujii, S.; Haneda, M.; Patel, T.; et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. *Cancer Sci.* **2020**, *111*, 98–111. [[CrossRef](#)]
82. Wei, T.; Zhang, X.; Zhang, Q.; Yang, J.; Chen, Q.; Wang, J.; Li, X.; Chen, J.; Ma, T.; Li, G.; et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. *Cancer Lett.* **2019**, *452*, 237–243. [[CrossRef](#)] [[PubMed](#)]
83. Yang, Z.; LaRiviere, M.J.; Ko, J.; Till, J.E.; Christensen, T.; Yee, S.S.; Black, T.A.; Tien, K.; Lin, A.; Shen, H.; et al. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. *Clin. Cancer Res.* **2020**, *26*, 3248–3258. [[CrossRef](#)] [[PubMed](#)]
84. Pang, Y.; Holmes, M.V.; Chen, Z.; Kartsonaki, C. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. *J. Gastroenterol. Hepatol.* **2019**, *34*, 330–345. [[CrossRef](#)] [[PubMed](#)]
85. Becker, A.E.; Hernandez, Y.G.; Frucht, H.; Lucas, A.L. Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. *World J. Gastroenterol.* **2014**, *20*, 11182–11198. [[CrossRef](#)]
86. Ghatnekar, O.; Andersson, R.; Svensson, M.; Persson, U.; Ringdahl, U.; Zeilon, P.; Borrebaeck, C.A. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. *Int. J. Cancer* **2013**, *133*, 2392–2397. [[CrossRef](#)] [[PubMed](#)]

87. Frampton, A.E.; Prado, M.M.; López-Jiménez, E.; Fajardo-Puerta, A.B.; Jawad, Z.A.R.; Lawton, P.; Giovannetti, E.; Habib, N.A.; Castellano, L.; Stebbing, J.; et al. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. *Oncotarget* **2018**, *9*, 19006–19013. [[CrossRef](#)] [[PubMed](#)]
88. Zhang, W.H.; Wang, W.Q.; Han, X.; Gao, H.L.; Li, T.J.; Xu, S.S.; Li, S.; Xu, H.X.; Li, H.; Ye, L.Y.; et al. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. *Comput. Struct. Biotechnol. J.* **2020**, *18*, 3606–3614. [[CrossRef](#)]
89. Almeida, P.P.; Cardoso, C.P.; de Freitas, L.M. PDAC-ANN: An artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression. *BMC Cancer* **2020**, *20*, 82. [[CrossRef](#)]
90. Muhammad, W.; Hart, G.R.; Nartowt, B.; Farrell, J.J.; Johung, K.; Liang, Y.; Deng, J. Pancreatic Cancer Prediction Through an Artificial Neural Network. *Front. Artif. Intell.* **2019**, *2*, 2. [[CrossRef](#)] [[PubMed](#)]
91. Marya, N.B.; Powers, P.D.; Chari, S.T.; Gleeson, F.C.; Leggett, C.L.; Abu Dayyeh, B.K.; Chandrasekhara, V.; Iyer, P.G.; Majumder, S.; Pearson, R.K.; et al. Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis. *Gut* **2020**. [[CrossRef](#)] [[PubMed](#)]
92. Khatri, I.; Bhasin, M.K. A Transcriptomics-Based Meta-Analysis Combined With Machine Learning Identifies a Secretory Biomarker Panel for Diagnosis of Pancreatic Adenocarcinoma. *Front. Genet.* **2020**, *11*, 572284. [[CrossRef](#)] [[PubMed](#)]
93. Chung, W.Y.; Correa, E.; Yoshimura, K.; Chang, M.C.; Dennison, A.; Takeda, S.; Chang, Y.T. Using probe electrospray ionization mass spectrometry and machine learning for detecting pancreatic cancer with high performance. *Am. J. Transl. Res.* **2020**, *12*, 171–179. [[PubMed](#)]
94. Sollie, S.; Michaud, D.S.; Sarker, D.; Karagiannis, S.N.; Josephs, D.H.; Hammar, N.; Santaolalla, A.; Walldius, G.; Garmo, H.; Holmberg, L.; et al. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. *BMC Cancer* **2019**, *19*, 858. [[CrossRef](#)]
95. de la Fuente, J.; Sharma, A.; Chari, S.; Majumder, S. Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. *Pancreatol* **2019**, *19*, 1043–1048. [[CrossRef](#)]
96. Cui, Y.; Shu, X.O.; Li, H.L.; Yang, G.; Wen, W.; Gao, Y.T.; Cai, Q.; Rothman, N.; Yin, H.Y.; Lan, Q.; et al. Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. *Int. J. Cancer* **2017**, *141*, 2423–2429. [[CrossRef](#)] [[PubMed](#)]
97. Jenkinson, C.; Elliott, V.L.; Evans, A.; Oldfield, L.; Jenkins, R.E.; O'Brien, D.P.; Apostolidou, S.; Gentry-Maharaj, A.; Fourkala, E.O.; Jacobs, I.J.; et al. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. *Clin. Cancer Res.* **2016**, *22*, 1734–1743. [[CrossRef](#)] [[PubMed](#)]
98. O'Brien, D.P.; Sandanayake, N.S.; Jenkinson, C.; Gentry-Maharaj, A.; Apostolidou, S.; Fourkala, E.O.; Camuzeaux, S.; Blyuss, O.; Gunu, R.; Dawnay, A.; et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: Implications for early disease detection. *Clin. Cancer Res.* **2015**, *21*, 622–631. [[CrossRef](#)]
99. Capello, M.; Bantis, L.E.; Scelo, G.; Zhao, Y.; Li, P.; Dhillon, D.S.; Patel, N.J.; Kundnani, D.L.; Wang, H.; Abbruzzese, J.L.; et al. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. *J. Natl. Cancer Inst.* **2017**, *109*, djw266. [[CrossRef](#)] [[PubMed](#)]
100. Mirus, J.E.; Zhang, Y.; Li, C.I.; Lokshin, A.E.; Prentice, R.L.; Hingorani, S.R.; Lampe, P.D. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. *Clin. Cancer Res.* **2015**, *21*, 1764–1771. [[CrossRef](#)] [[PubMed](#)]
101. Magis, A.T.; Rappaport, N.; Conomos, M.P.; Omenn, G.S.; Lovejoy, J.C.; Hood, L.; Price, N.D. Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis. *Sci. Rep.* **2020**, *10*, 16275. [[CrossRef](#)]
102. Moore, H.M.; Kelly, A.B.; Jewell, S.D.; McShane, L.M.; Clark, D.P.; Greenspan, R.; Hayes, D.F.; Hainaut, P.; Kim, P.; Mansfield, E.A.; et al. Biospecimen reporting for improved study quality (BRISQ). *Cancer Cytopathol.* **2011**, *119*, 92–101. [[CrossRef](#)] [[PubMed](#)]
103. Cohen, J.F.; Korevaar, D.A.; Altman, D.G.; Bruns, D.E.; Gatsonis, C.A.; Hooft, L.; Irwig, L.; Levine, D.; Reitsma, J.B.; de Vet, H.C.W.; et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. *BMJ Open* **2016**, *6*, e012799. [[CrossRef](#)]
104. Altman, D.G.; McShane, L.M.; Sauerbrei, W.; Taube, S.E. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. *PLoS Med.* **2012**, *9*, e1001216. [[CrossRef](#)]
105. Schulz, K.F.; Altman, D.G.; Moher, D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. *BMJ* **2010**, *340*, c332. [[CrossRef](#)]
106. Crosby, D.; Lyons, N.; Greenwood, E.; Harrison, S.; Hiom, S.; Moffat, J.; Quallo, T.; Samuel, E.; Walker, I. A roadmap for the early detection and diagnosis of cancer. *Lancet Oncol.* **2020**, *21*, 1397–1399. [[CrossRef](#)]
107. Kunovsky, L.; Tesarikova, P.; Kala, Z.; Kroupa, R.; Kysela, P.; Dolina, J.; Trna, J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. *Can. J. Gastroenterol. Hepatol.* **2018**, *2018*, 5389820. [[CrossRef](#)] [[PubMed](#)]
108. Paulovich, A.G.; Whiteaker, J.R.; Hoofnagle, A.N.; Wang, P. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. *Proteom. Clin. Appl.* **2008**, *2*, 1386–1402. [[CrossRef](#)]
109. Rifai, N.; Gillette, M.A.; Carr, S.A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. *Nat. Biotechnol.* **2006**, *24*, 971–983. [[CrossRef](#)] [[PubMed](#)]
110. Root, A.; Allen, P.; Tempst, P.; Yu, K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. *Cancers* **2018**, *10*, 67. [[CrossRef](#)] [[PubMed](#)]
111. Immunovia. Available online: <https://immunovia.com/about-us> (accessed on 25 August 2020).

112. Debernardi, S.; O'Brien, H.; Algahmdi, A.S.; Malats, N.; Stewart, G.D.; Plješa-Ercegovac, M.; Costello, E.; Greenhalf, W.; Saad, A.; Roberts, R.; et al. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study. *PLoS Med.* **2020**, *17*, e1003489. [[CrossRef](#)] [[PubMed](#)]
113. Blyuss, O.; Zaikin, A.; Cherepanova, V.; Munblit, D.; Kiseleva, E.M.; Prytomanova, O.M.; Duffy, S.W.; Crnogorac-Jurcevic, T. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. *Br. J. Cancer* **2020**, *122*, 692–696. [[CrossRef](#)]
114. Clinicaltrials.gov. Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (UroPanc). Available online: <https://clinicaltrials.gov/ct2/show/NCT04449406> (accessed on 3 March 2021).
115. Cohen, J.D.; Li, L.; Wang, Y.; Thoburn, C.; Afsari, B.; Danilova, L.; Douville, C.; Javed, A.A.; Wong, F.; Mattox, A.; et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science* **2018**, *359*, 926–930. [[CrossRef](#)]
116. Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Swanton, C.; Seiden, M.V.; Consortium, C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann. Oncol.* **2020**, *31*, 745–759. [[CrossRef](#)]
117. Killock, D. CancerSEEK and destroy—A blood test for early cancer detection. *Nat. Rev. Clin. Oncol.* **2018**, *15*, 133. [[CrossRef](#)]